Nkarta, Inc. (NKTX) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Nkarta, Inc.
Address
1150 Veterans Boulevard
South San Francisco, CA 94080
United States of America (the)
Phone
415 582 4923
Website
Sector
Healthcare
Industry
Biotechnology
Employees
106
First IPO Date
July 10, 2020
Key Executives
| Name | Title | Pay | Year Born |
| Paul J. Hastings | Chief Executive Officer & Director | 1.03M | 1960 |
| Shawn Rose | Chief Medical Officer and Head of Research & Development | 515,473 | N/A |
| Nadir Mahmood | President and Principal Accounting & Financial Officer | 806,361 | 1980 |
Description
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
